During the past few decades, advancements made in multiple sclerosis (MS) research have revolutionized the field. Thus far in 2017, the brisk pace has continued. The American Academy of Neurology (AAN) meeting in April 2017 in Boston, Massachusetts and the Consortium of MS Centers Conference (CMSC) in May 2017 in New Orleans, Louisiana were both […]

The Multiple Sclerosis Association of America is pleased to announce three new resources for the multiple sclerosis (MS) community. These new publications are available free-of-charge as both printed and online versions on mymsaa.org. MSAA’s award-winning magazine, The Motivator, provides valuable information and support for individuals living with MS, their care partners, family members, and medical […]

A new mobile and cloud-based health technology offered by Bayer has been approved by the United States Food and Drug Administration (FDA) for individuals taking Betaseron for relapsing-remitting MS. On May 30, 2017, Bayer announced the approval of myBETAapp™ and the BETACONNECT Navigator™. With this software, in conjunction with Bluetooth technology, individuals using the electronic […]

An individual with multiple sclerosis (MS) in Germany has developed progressive multifocal leukoencephalopathy (PML) following three years of treatment with Tysabri® (natalizumab) and one dose of Ocrevus™ (ocrelizumab). PML is a potentially fatal brain infection that can occur in people with a weakened immune system, which can result from taking an immunosuppressant. An increased risk […]

On March 28, 2017, the United States Food and Drug Administration (FDA) announced the approval of Ocrevus™ (ocrelizumab) for the treatment of two types of multiple sclerosis (MS): relapsing forms of MS (RMS) and primary-progressive MS (PPMS). This is the first time that a medication for MS has been approved for two types of the […]